



University of Southern Denmark

**Evaluation of point-of-care multiplex polymerase chain reaction in guiding antibiotic treatment of patients acutely admitted with suspected community-acquired pneumonia in Denmark
A multicentre randomised controlled trial**

Cartuliales, Mariana Bichuette; Rosenvinge, Flemming Schønning; Mogensen, Christian Backer; Skovsted, Thor Aage; Andersen, Steen Lomborg; Østergaard, Claus; Pedersen, Andreas Kristian; Skjøt-Arkil, Helene

Published in:
PLoS Medicine

DOI:
[10.1371/journal.pmed.1004314](https://doi.org/10.1371/journal.pmed.1004314)

Publication date:
2023

Document version:
Final published version

Document license:
CC BY

Citation for pulished version (APA):

Cartuliales, M. B., Rosenvinge, F. S., Mogensen, C. B., Skovsted, T. A., Andersen, S. L., Østergaard, C., Pedersen, A. K., & Skjøt-Arkil, H. (2023). Evaluation of point-of-care multiplex polymerase chain reaction in guiding antibiotic treatment of patients acutely admitted with suspected community-acquired pneumonia in Denmark: A multicentre randomised controlled trial. *PLoS Medicine*, 20(11), Article e1004314. <https://doi.org/10.1371/journal.pmed.1004314>

Go to publication entry in University of Southern Denmark's Research Portal

Terms of use

This work is brought to you by the University of Southern Denmark.
Unless otherwise specified it has been shared according to the terms for self-archiving.
If no other license is stated, these terms apply:

- You may download this work for personal use only.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying this open access version

If you believe that this document breaches copyright please contact us providing details and we will investigate your claim.
Please direct all enquiries to puresupport@bib.sdu.dk

RESEARCH ARTICLE

Evaluation of point-of-care multiplex polymerase chain reaction in guiding antibiotic treatment of patients acutely admitted with suspected community-acquired pneumonia in Denmark: A multicentre randomised controlled trial

Mariana Bichuette Cartulieres^{1,2*}, Flemming Schønning Rosenvinge^{3,4}, Christian Backer Mogensen^{1,2}, Thor Aage Skovsted⁵, Steen Lomborg Andersen⁶, Claus Østergaard⁷, Andreas Kristian Pedersen⁸, Helene Skjøt-arkil^{1,2}

1 Department of Emergency Medicine, University Hospital of Southern Denmark, Aabenraa, Denmark, **2** Department of Regional Health Research, University of Southern Denmark, Aabenraa, Denmark, **3** Department of Clinical Microbiology, Odense University Hospital, Odense, Denmark, **4** Research Unit of Clinical Microbiology, University of Southern Denmark, Odense, Denmark, **5** Department of Biochemistry and Immunology, University Hospital of Southern Denmark, Aabenraa, Denmark, **6** Department of Clinical Microbiology, University Hospital of Southern Denmark, Aabenraa, Denmark, **7** Department of Clinical Microbiology, Lillebaelt Hospital, Vejle, Denmark, **8** Department of Clinical Research, University Hospital of Southern Denmark, Aabenraa, Denmark

* mbc@rsyd.dk


Abstract

Background

Rapid and accurate detection of pathogens is needed in community-acquired pneumonia (CAP) to enable appropriate antibiotics and to slow the development of antibiotic resistance. We aimed to compare the effect of point-of-care (POC) polymerase chain reaction (PCR) detection of respiratory pathogens added to standard care with standard care only (SCO) on antibiotic prescriptions after acute hospital admission.

Methods and findings

We performed a superiority, parallel-group, open-label, multicentre, randomised controlled trial (RCT) in 3 Danish medical emergency departments (EDs) from March 2021 to February 2022. Adults acutely admitted with suspected CAP during the daytime on weekdays were included and randomly assigned (1:1) to POC-PCR (The Biofire FilmArray Pneumonia Panel plus added to standard care) or SCO (routine culture and, if requested by the attending physician, target-specific PCR) analysis of respiratory samples. We randomly assigned 294 patients with successfully collected samples (tracheal secretion 78.4% or expectorated sputum 21.6%) to POC-PCR ($n = 148$, 50.4%) or SCO (146, 49.6%). Patients and investigators owning the data were blinded to the allocation and test results. Outcome adjudicators and clinical staff at the ED were not blinded to allocation and test results but were together



OPEN ACCESS

Citation: Cartulieres MB, Rosenvinge FS, Mogensen CB, Skovsted TA, Andersen SL, Østergaard C, et al. (2023) Evaluation of point-of-care multiplex polymerase chain reaction in guiding antibiotic treatment of patients acutely admitted with suspected community-acquired pneumonia in Denmark: A multicentre randomised controlled trial. *PLoS Med* 20(11): e1004314. <https://doi.org/10.1371/journal.pmed.1004314>

Academic Editor: Jean-Louis Vincent, Erasme University Hospital, BELGIUM

Received: May 22, 2023

Accepted: October 26, 2023

Published: November 28, 2023

Copyright: © 2023 Cartulieres et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: We have added the information below + a data sharing plan to supporting information. Anonymized personal data is not subject to data protection legislation by the General Data Protection Regulation (GDPR) in the EU and is therefore allowed to be publicly shared. However, the personal data underlying the results in the article is not possible fully anonymize and is therefore covered by § 10 of the Danish Data

Protection Act. When personal data covered by Section 10 of the Data Protection Act (also applies to pseudonymized information) wishes to be passed on with a view to publication in a recognized scientific journal, it requires permission from the Danish Data Protection Authority, cf. Section 10, subsection of the Data Protection Act. 3, No. 3. However, the Danish Data Protection Authority can only approve this sharing if there is an authority in the informed consent from the ethical approval cf. Section 2, subsection 10 of the Danish Committees Act. In the ethical approval, S-20200188 underlying this project is it stated that personal data is anonymized upon publication. It is, therefore, not possible to share pseudonymized information unrestricted. Upon request, the project sponsor Christian Backer Mogensen can apply to the Regional Committee for Health Research Ethics, Southern Denmark for an additional supplement of the protocol. This ethical protocol supplement will explain and describe the reason for transfer of the project's personal data to a third party without consent. Such a request can be sent to fortegnelsen-SHS@rsyd.dk marked attention special consultant Signe Bek Sørensen, Kresten Philipssensvej 15, 6200 Aabenraa, Denmark.

Funding: This work was supported by the Region of Southern Denmark: <https://regionsyddanmark.dk/en/about-us/the-region-of-southern-denmark> (grant: 144.000 DKK, grant number A583 to HSA), University of Southern Denmark: <https://www.sdu.dk/en> (grant: one year salary, grant number 17/10636 to MBC), and Hospital Sønderjylland: <https://sygehussonderjylland.dk/> (grant: two years salary, grant number 20/20505 to MBC). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: The authors have declared that no competing interests exist.

Abbreviations: CAP, community-acquired pneumonia; CI, confidence interval; COVID-19, Coronavirus Disease 2019; ED, emergency department; ICU, intensive care unit; LOS, length of stay; LRT, lower respiratory tract; OR, odds ratio; PCR, polymerase chain reaction; POC, point-of-care; RCT, randomised controlled trial; SCO, standard care only.

with the statistician, blinded to data management and analysis. Laboratory staff performing standard care analyses was blinded to allocation. The study coordinator was not blinded. Intention-to-treat and per protocol analysis were performed using logistic regression with Huber–White clustered standard errors for the prescription of antibiotic treatment. Loss to follow-up comprises 3 patients in the POC-PCR (2%) and none in the SCO group. Intention-to-treat analysis showed no difference in the primary outcome of prescriptions of no or narrow-spectrum antibiotics at 4 h after admission for the POC-PCR ($n = 91$, 62.8%) odds ratio (OR) 1.13; (95% confidence interval (CI) [0.96, 1.34] $p = 0.134$) and SCO ($n = 87$, 59.6%). Secondary outcomes showed that prescriptions were significantly more targeted at 4-h OR 5.68; (95% CI [2.49, 12.94] $p < 0.001$) and 48-h OR 4.20; (95% CI [1.87, 9.40] $p < 0.001$) and more adequate at 48-h OR 2.11; (95% CI [1.23, 3.61] $p = 0.006$) and on day 5 in the POC-PCR group OR 1.40; (95% CI [1.18, 1.66] $p < 0.001$). There was no difference between the groups in relation to intensive care unit (ICU) admissions OR 0.54; (95% CI [0.10, 2.91] $p = 0.475$), readmission within 30 days OR 0.90; (95% CI [0.43, 1.86] $p = 0.787$), length of stay (LOS) IRR 0.82; (95% CI [0.63, 1.07] $p = 0.164$), 30 days mortality OR 1.24; (95% CI [0.32, 4.82] $p = 0.749$), and in-hospital mortality OR 0.98; (95% CI [0.19, 5.06] $p = 0.986$).

Conclusions

In a setting with an already restrictive use of antibiotics, adding POC-PCR to the diagnostic setup did not increase the number of patients treated with narrow-spectrum or without antibiotics. POC-PCR may result in a more targeted and adequate use of antibiotics. A significant study limitation was the concurrent Coronavirus Disease 2019 (COVID-19) pandemic resulting in an unusually low transmission of respiratory virus.

Trial registration

ClinicalTrials.gov ([NCT04651712](https://clinicaltrials.gov/ct2/show/study/NCT04651712)).

Author summary

Why was this study done?

- The global rise in antimicrobial resistance fueled by the excessive use and misuse of antibiotics is a major public health concern.
- Fast and accurate diagnostics is important to counteract this development as it can potentially reduce the use of antibiotics/broad-spectrum antibiotics without sacrificing patient safety.
- Pneumonia is a common, serious condition where available point-of-care (POC) technology (polymerase chain reaction) allows clinicians to detect possible airway pathogens before treatment decisions are made.

What did the researchers do and find?

- In this randomised trial of 294 patients admitted with suspected pneumonia, POC did not result in the prescription of less antibiotics or less broad-spectrum antibiotics within 4 h after admission.
- Based on a subset of patients, the results indicated that more patients in the POC-group were treated with targeted or appropriate antibiotics 48 h and 5 days after admission.
- Patients in the POC-group had a non-statistically significant reduction in length of hospital stay of approximately 1 day.

What do these findings mean?

- The use of respiratory POC does not seem to be an effective tool for reducing the use of antibiotics in a setting with a very low level of antimicrobial resistance and already prudent use of antibiotics.
- The use of respiratory POC may aid to ensure a targeted and/or appropriate treatment in a setting with a restrictive use of antibiotics—and thereby may aid to sustain a restrictive strategy.
- The concurrent Coronavirus Disease 2019 (COVID-19) pandemic and the unusually low transmission of common respiratory viruses in the period may have affected the results.

Introduction

Community-acquired pneumonia (CAP) is a leading cause of hospitalisation and mortality [1,2]. Antibiotic treatment should be initiated timely [3] to avoid serious complications such as bacteremia, sepsis, organ failure, and death [4]. Initial antimicrobial treatment is often empiric, and an uncertain or delayed diagnosis often leads to use of broad-spectrum antibiotics [5]. This, in turn, contributes to adverse effects and complications, such as *Clostridioides difficile* infection, super-infections with resistant bacteria, poor patient outcomes, and general development of antibiotic resistance [6–9]. In Denmark antimicrobial resistance is low, and almost all *Streptococcus pneumoniae* are susceptible to benzylpenicillin and 93% to erythromycin, and 75% of *Haemophilus influenzae* are susceptible to benzylpenicillin [10]. Danish guidelines recommend narrow-spectrum penicillin for empirical treatment of CAP with CURB-65 <3 and broad-spectrum antibiotics for severe CAP with CURB-65 ≥3 [11,12]. The CAP diagnosis is based on clinical symptoms such as cough, dyspnea, fever, and sputum production, combined with unspecific diagnostic tools such as auscultation of the lungs, chest radiography, blood tests, and microbiological analysis of sputum samples [13–15].

Sputum samples can be cultivated to determine bacterial agents; however, samples are often of poor quality, many patients cannot deliver a sample and laboratory turnaround time is typically 2 days [16,17]. The lack of precise, timely microbiological results may delay or hinder targeted antimicrobial treatment.

In addition, CAP is often caused by viral infections that can be treated without antibiotics but usually are indistinguishable from bacterial infections without specific microbiological tests [18–20]. Consequently, molecular diagnostic methods, including rapid polymerase chain reaction (PCR) panels for viruses and bacteria, have been developed and tested in clinical settings [21–23]. These panels are simple to use, sensitive, generate rapid results, and significantly contribute to the management of CAP [21,23,24].

By identifying pathogenic organisms earlier, studies have reported faster de-escalation of antibiotic treatment, reduced duration of broad-spectrum empirical antibiotic therapy, reduced length of stay (LOS), and reduced hospital costs [25,26]. However, evidence of clinical impact of point-of-care (POC)-PCR testing of sputum samples in EDs is limited and a recent feasibility study advocates the need for randomised controlled trials (RCTs) to test POC-PCR panels in acute settings [27].

In this multicentre, randomised study, we aimed to investigate the effect of adding POC-PCR to standard care in an emergency department (ED) setting. Our hypothesis was that POC-PCR testing of sputum samples from suspected CAP patients would increase the proportion of patients treated with no or narrow-spectrum antibiotics. The objectives were (i) to investigate the effect of POC-PCR testing of sputum from suspected CAP patients on the prescriptions of antibiotic treatment compared to usual care; and (ii) to investigate if the addition of POC-PCR testing to the diagnostic setup affects LOS, intensive care unit (ICU) admission, 30-days mortality, in-hospital mortality, or readmissions within 30 days.

Methods

Trial design

This study was designed as a superiority, parallel-armed, multicentre randomised controlled clinical trial, and was part of a large multifaceted clinical study “INfectious Diseases in EmERgency Department” (INDEED) [28].

The study was reported in accordance with the Consolidation Standard of Reporting Trials (CONSORT) guidelines (see [S1 Text](#)) [29]. The processing of personal data is notified to and approved by the Region of Southern Denmark and listed in the internal record (no. 20/60508) cf. Art 30 of The EU General Data Protection Regulation and approved by the Regional Committee on Health Research Ethics for Southern Denmark (S-20200188), registered by [ClinicalTrials.gov](#) (NCT04651712), and conducted according to the Declaration of Helsinki-Ethical principle for medical research involving human subjects. The study protocol (see [S2 Text](#)) has been published and includes further information about the methods [28].

Setting

The trial was conducted in 3 Danish medical EDs with a coverage of approximately 750,000 inhabitants: 2 regional hospitals, Lillebælt Hospital in Kolding and Hospital Sønderjylland in Aabenraa, and 1 university hospital, Odense University Hospital in Odense. Based on data from the National Health Data Agency and Statistics Denmark, the mean hospital LOS for patients >65 years old hospitalised in departments with medical specialties (including pneumonia) was of 5.9 days in 2018 [30], and local data from the 3 hospitals included in this study, reported a mean LOS of 3.8 days in hospital for adult patients (>18 years) discharged with pneumonia diagnose during the study period. According to clinical guidelines, patients admitted to the ED in our institutions must have a clinical assessment within half an hour to clarify suspicion of infection and disease severity. If the ED physician suspects CAP, diagnostic biomarkers, chest X-ray, and tracheal suctioning/aspirates, or expectorated sputum are performed without delay [11,12]. If indicated, empirical treatment must be initiated within 4 h, and the

treatment must be documented in the patient medical chart. The empirical treatment guidelines for CAP are presented in [S1 Table](#), and the timeline for the standard procedures in the EDs is presented in [S2 Table](#).

Participants

Adults aged 18 years or older admitted to the ED were invited to participate in the study if the attending physician suspected CAP and the patient had at least one of the following pulmonary symptoms: dyspnea, cough, expectoration, chest pain, or fever. Patients were excluded if: they could not deliver a sputum sample, participation delayed urgent treatment, the patient was transferred to an ICU, the patient had been admitted within the last 14 days, had Coronavirus Disease 2019 (COVID-19) infection at admission, was pregnant, or had severe immunodeficiencies (HIV-positive, with a cluster of differentiation 4 cell count <200), treatment with immunosuppressive medicine (Anatomical Therapeutic Chemical classification L04A), corticosteroids (>20 mg/day prednisone or equivalent for >14 days within the last 30 days), or chemotherapy within 30 days [28]. If patients fulfilled the eligibility criteria, the study assistant obtained verbal and written consent (see [S3 Text](#)) which was documented and witnessed at the bedside immediately after clinical assessment and before inclusion in the study. Patients were recruited consecutively Monday through Friday from 10 AM to 8 PM.

Randomisation and masking

The patient was randomly assigned to one of 2 groups with 1:1 allocation: (i) POC-PCR analysis (Biofire FilmArray Pneumonia Panel plus, Biomérieux, Marcy l'Etoile, France) [31] in addition to standard care; or (ii) standard care only (SCO) as control. The randomisation was generated electronically using Research Electronic Data Capture Randomisation Module [32]. Computer-generated random lists were prepared by an independent data manager with permuting blocks of varying size and stratified according to sites. Allocation concealment was ensured, as randomisation was performed electronically, and the study assistants administering the randomisation did not have access to the randomisation code. The allocation was not revealed to the project assistant before consent was obtained and specimen collected. Patients and investigators owning the data were blinded to the allocation and test results. Outcome adjudicators and clinical staff at the ED were not blinded to allocation and test results but were together with the statistician, blinded to data management and analysis. Laboratory staff performing standard care analyses was blinded to allocation. The study coordinator was not blinded.

Procedure

Tracheal secretion is the recommended sampling method by Danish national and regional guidelines [11,12], but expectorated sputum is accepted if the patient can not cooperate during the procedure. Lower respiratory tract (LRT) specimens were collected right after enrolment by a project assistant. Tracheal suction/aspiration was performed with a catheter (EXTRUDAN Surgery Aps, Denmark, CH12, 530 mm) insertion into the nares during inhalation. The catheter was gently advanced about 40 cm into the trachea, where suctioning at 200 to 400 mmHg was performed before withdrawing the catheter. POC-PCR analysis was done without delay in a POC laboratory. The POC laboratory had 24-h coverage and was situated in the ED (2 sites) or close to the department (transport time less than 10 min, 1 site). Project assistants and laboratory staff were trained in the use of the POC-PCR system, and each site had a pocket laboratory protocol to ensure sample quality and safe handling of specimens. Within 4 h after the patient was admitted, the result of the POC-PCR was handed to the treating physician

along with a guideline-based action card (see [S4 Text](#)) recommending specific treatments matching different POC-PCR results. In case of any additional questions, the physician was encouraged to contact the local clinical microbiologist for further advice. All 6 project assistants received bedside training in tracheal suction to ensure consistent data collection. Clinical and patient data were retrieved by chart review and patient interview as described in the protocol [28].

Intervention

Point-of-care polymerase chain reaction (POC-PCR). The Biofire FilmArray Pneumonia Panel plus (Biomérieux, Marcy l’Etoile, France) is an automatic, closed, multiplex PCR, that includes all steps of molecular diagnostics in about 75 min, including sample preparation. The panel detects 18 bacterial pathogens, 9 viruses, and 7 antimicrobial resistance genes (see [S3 Table](#)).

Results for typical colonising bacteria were reported semiquantitatively providing estimates to the nearest whole log as gene copies/ml ranging from 10^4 to 10^7 copies/ml. Biofire FilmArray Pneumonia Panel was used in accordance with the manufacturer’s instructions at all 3 sites [31]. All POC-PCR results were registered directly in a study database and in the patient’s medical chart.

Standard care (routine culture and PCR). All samples were submitted to standard-of-care procedures of microbiological testing. Part of the sputum sample was transferred to a 5% blood agar plate and to a chromogenic and/or selective agar. The inoculum was streaked over the agar surface and blood agar plates were inoculated with a *Staphylococcus* streak to allow growth of *H. influenzae*. Blood agar plates were incubated in a 5% CO₂ atmosphere, other plates at 35°C in normal atmospheric conditions. After 1 to 2 days of incubation, pathogens were identified by Matrix-Assisted Laser Desorption/Ionisation-time of flight and reported semiquantitatively as few, some, or numerous. In addition, “no growth of pathogens” and “upper airway microbiota” were reported. Routine PCR was performed if requested by the referring physician (e.g., for *Legionella pneumophila* or influenza virus). The results were registered in the microbiological laboratory information system (MADS, Aarhus University Hospital, Aarhus, Denmark) and were accessible from the patient’s medical chart.

Outcomes

The primary outcome was the prescription of “no or narrow-spectrum” antibiotics within 4 h after admission. Narrow-spectrum antibiotics were defined as antibiotics active against CAP pathogens: Beta-lactamase sensitive penicillins (phenoxymethylpenicillin or benzylpenicillin), extended spectrum beta-lactamase sensitive penicillins (ampicillin/amoxicillin/pivampicillin). In case of penicillin allergy: macrolides and cefuroxime were also defined as narrow-spectrum antibiotics (see [S4 Table](#)). We pooled narrow-spectrum and no antibiotics, as our focus was rational and restrictive use of antibiotics [11,12]. As our main focus was to study POC-PCR from an antibiotic stewardship perspective, we decided to handle no and narrow-spectrum antibiotics as our primary outcome and targeted antibiotics as a secondary outcome. In the initial protocol, no, narrow-spectrum, and targeted antibiotics were treated as a composite primary outcome [28].

Secondary outcomes

- Prescription of no or narrow-spectrum antibiotics at 48 h and 5 days after admission.

- Prescription of targeted antibiotics within 4 h, 48 h, and 5 days. Targeted antibiotics were defined as either narrow-spectrum antibiotics targeting CAP or antibiotics directed against a detected bacterial pathogen identified by culture.
- Prescription of adequate antibiotics within 4 h, 48 h, and 5 days. Adequate antibiotics were defined as all antibiotics covering the detected bacterial pathogen.

We categorised antibiotic treatment as targeted and/or adequate in relation to the following pathogens identified by culture: *S. pneumoniae*, *H. influenzae*, *Moraxella catarrhalis*, *Pseudomonas aeruginosa*, *Staphylococcus aureus*, hemolytic streptococci, and *L. pneumophila* (see [S5 Table](#)). We excluded *Enterobacterales*, *Acinetobacter*, and yeast as they usually represent colonisation and are less likely to cause CAP.

Data on other secondary outcomes were extracted from the patients' medical chart: 30 days mortality (death within 30 days from admission to the ED), in-hospital mortality (death during the current hospitalisation, ICU admission during the current hospitalisation, readmission within 30 days after discharge and LOS (days from admission to discharge)).

Statistical methods

Based on literature and local data, we assumed that adherence to antimicrobial guidelines was 50% for the management of CAP patients [33], and we required at least 200 patients with suspected CAP with two-sided 5% significance to achieve a power of 82% to detect a minimal difference of 20% prescription of no or narrow-spectrum treatment in the POC-PCR group compared to the control group. However, more patients were included, so the power calculation was repeated without changing earlier assumptions before the commencement of statistical analysis and with the statistician blinded to the allocation groups and the general distribution of the data. The new calculation yielded a power of 94% with 290 patients with two-sided 5% significance.

Descriptive statistics were conducted to assess whether the exchangeability assumption was met for the baseline variables. To assess whether there was a difference between the 2 groups Fisher's exact test or chi-square test were performed for categorical variables, and *t* test or Wilcoxon rank sum test for non-categorical variables.

To accommodate the variation between study sites, we used logistic regression with Huber-White clustered standard errors to investigate the effect of POC-PCR on antibiotic prescription at 4 h, for the secondary outcomes at 48 h, and 5 days. Results were reported with odds ratio (OR) and 95% confidence intervals (CIs). To compare the 2 groups, we used negative binomial regression for LOS. Logistic regression analyses were performed for 30 days mortality, in-hospital mortality, ICU admission, and readmission within 30 days and unadjusted and adjusted for triage. Multiple imputation using a logistic regression was performed to handle missing outcome data. We realised 50 imputations of target treatment at 4 h based on CURB-65 and age as they may be good predictors for antibiotic treatment prescriptions. We considered a two-sided *p*-value less than 0.05 statistically significant, and no adjustments for multiple testing were utilised. Statistical analyses were performed using STATA 17.0 (Texas, United States of America).

Results

Patients admitted with suspected CAP were enrolled from March 1, 2021 to February 28, 2022. The last follow-up for mortality and readmission was on April 1, 2022. We screened 379 patients for eligibility and collected 294 (77.6%) LRT samples (78.4% tracheal secretions and 21.6% expectorated sputa) from patients who underwent randomisation. The 294 patients




Fig 1. Trial profile. LRT, lower respiratory tract; POC-PCR, point-of-care polymerase chain reaction; SCO, standard care only.

<https://doi.org/10.1371/journal.pmed.1004314.g001>

were allocated to either the POC-PCR group (148 patients (50.4%)) or the SCO group (146 patients (49.6%)), and those patients were included in the intention-to-treat analysis. Per protocol analyses for the primary outcome included 291 (99.0%) patients with no or narrow antibiotic treatment registered within 4 h (POC-PCR 145 (49.8%) and SCO 146 (50.2%)) (Fig 1).

Baseline data

Demographic and clinical characteristics are shown in Table 1.

Number of patients prescribed “no or narrow,” targeted, and adequate antibiotic at 4 h, 48 h, and 5 days is presented in Table 2. Because of the observed difference in triage between the intervention and control, unadjusted and adjusted results are presented in Tables 3 and 4.

Prescription of no or narrow-spectrum antibiotics

There were 3 missing samples due to POC-PCR assay failure. Thus, no clinical characteristics influenced the missing mechanism. Therefore, we believe the data are missing completely at random. However, for sensitivity reasons, multiple imputation was performed. Results from per protocol and intention-to-treat analysis were similar. POC-PCR was not superior to SCO regarding prescriptions of no or narrow-spectrum antibiotics within 4 h after admission. Intention-to-treat analyses of 294 patients yielded an OR 1.13; (95% CI [0.96, 1.34] $p = 0.134$), and per protocol analysis of 291 patients resulted in an OR 1.14; (95% CI [0.97, 1.34] $p = 0.101$). We found a statistically significant difference on day 5 but not 48 h after admission (Table 3).

Prescription of targeted and adequate antibiotics

Prespecified analysis of targeted antibiotic treatment and exploratory analyses of adequate antibiotics were based on positive culture results from 290 specimens after exclusion of one

Table 1. Baseline characteristics of patients included in the analysis.

Allocation	SCO n = 146	POC-PCR n = 145	Total n = 291
Age, median years (IQR)	72.5 (59.0; 81.0)	74.0 (61.5; 81.0)	73.0 (60.0; 81.0)
Gender (male), n (%)	70 (47.9)	78 (53.8)	148 (51.0)
Activities of daily living ^a , n (%)	45 (31.0)	33 (22.3)	78 (26.6)
Nursing home resident, n (%)	15 (10.3)	14 (9.5)	29 (9.9)
Patients with a confirmed CAP diagnosis ^b , n (%)	83 (56.8)	89 (61.4)	172 (59.1)
HRCT findings suggestive of pneumonia, n (%)	66 (45.2)	79 (54.5)	145 (49.8)
Type of respiratory samples, n (%)			
Tracheal secretions	112 (76.7)	116 (80.0)	228 (78.4)
Expectorated sputa	34 (23.3)	29 (20.0)	63 (21.6)
Blood culture, n (%)	127 (86.9)	120 (83.3)	247 (85.2)
Bloodstream infections	12 (8.2)	6 (4.1)	18 (6.2)
Urine culture, n (%)	124 (84.9)	119 (82.6)	243 (83.8)
Bacteriuric	25 (20.2)	34 (28.3)	59 (24.2)
SYMPTOMS			
Cough n (%)	102 (71.3)	104 (72.2)	206 (71.8)
Expectoration, n (%)	85 (59.4)	78 (54.2)	163 (56.8)
Breast tightness, n (%)	44 (31.2)	46 (31.7)	90 (31.5)
Dyspnea, n (%)	104 (72.7)	108 (75.0)	212 (73.9)
SEVERITY ASSESSMENT			
CURB-65 ^d ≥3, n (%)	24 (16.4)	18 (12.4)	42 (14.4)
Glasgow Coma Scale <15, n (%)	7 (4.8)	6 (4.1)	13 (4.4)
Triage ≥2, n (%)	62 (42.5)	40 (27.6)	102 (35.1)†
COMORBIDITIES			
Chronic obstructive pulmonary disease, n (%)	42 (28.8)	51 (35.2)	93 (32.0)
Neurological disease, n (%)	27 (18.5)	28 (19.3)	55 (19.0)
Cardiovascular disease, n (%)	56 (38.4)	62 (42.8)	118 (40.5)
Endocrinological disease, n (%)	49 (33.6)	43 (29.7)	92 (31.6)
VITAL PARAMETERS			
Oxygen saturation, median (IQR)	94.0 (91.0; 96.0)	93.0 (92.0; 96.0)	94.0 (92.0; 96.0)
Respiratory frequency/min, median (IQR)	22.0 (20.0; 25.0)	20.0 (18.0; 24.0)	22.0 (18.0; 24.0)
Heart rate/min, mean (SD)	93.8 (18.2)	92.2 (17.6)	93.0 (17.9)
Systolic blood pressure mmHg, mean (SD)	134.7 (20.3)	135.4 (22.1)	135.0 (21.2)
Diastolic blood pressure mmHg, mean (SD)	75.2 (14.5)	76.0 (16.9)	75.6 (15.7)
Temperature °C, mean (SD)	37.6 (1.0)	37.5 (0.9)	37.6 (1.0)
BLOOD TESTS			
C-reactive protein mg/L, median (IQR)	86.5 (30.8; 170.8)	82.0 (30.5; 178.0)	82.0 (31.0; 174.0)
Leucocytes 10 ⁹ /L, median (IQR)	11.1 (8.5; 15.6)	11.3 (8.5; 14.8)	11.2 (8.5; 15.2)
Neutrophils 10 ⁹ /L, median (IQR)	8.2 (6.0; 13.1)	8.9 (6.2; 12.5)	8.7 (6.1; 12.6)
ANTIBIOTIC TREATMENT and VACCINE STATUS			
Antibiotic treatment before admission ^f , n (%)	38 (26.0)	36 (24.8)	74 (25.4)
Antibiotic treatment at admission, n (%)	32 (21.9)	30 (20.7)	62 (21.3)
Allergy to antibiotics, n (%)	9 (6.2)	12 (8.3)	21 (7.2)
Pneumococcal vaccine within 5 years, n (%)	75 (51.4)	84 (57.9)	159 (54.6)

(Continued)

Table 1. (Continued)

Allocation	SCO <i>n</i> = 146	POC-PCR <i>n</i> = 145	Total <i>n</i> = 291
Influenza vaccine (season 2020/2021), <i>n</i> (%)	103 (70.5)	105 (72.4)	208 (71.5)

Data are *n* (%): numbers (percentages), median (IQR: interquartile range), or mean (SD: standard deviation).

^aActivities of daily living: One or more dependencies related to bathing, dressing, toileting, transfer, continence, and eating.

^bThe confirmed CAP diagnosis was assigned by an expert panel of experienced emergency and infectious disease experts in acute infections based on all clinical information from the medical record within the first week of ED admission, including a chest computed tomography.

^cBacteriuria >10⁴ bacteria/mL (*Enterobacteriaceae*) or >10⁵ (others).

^dCURB-65: confusion, blood urea nitrogen >7 mmol/l, respiratory rate ≥30 breaths per minute, blood pressure <90 mmHg systolic or ≤60 mmHg diastolic, age ≥65 years.

^eTriage: Danish emergency process triage [34].

^fAntibiotic treatment within 1 month prior to admission.

[†]*p* = 0.001

CAP, community-acquired pneumonia; ED, emergency department; HRCT, high-resolution computed tomography; mmHg, millimetre(s) of mercury; mg/L, milligrammes per litre; POC-PCR, point-of-care polymerase chain reaction; SCO standard care only.

<https://doi.org/10.1371/journal.pmed.1004314.t001>

sample missing from the culture analysis. We identified 68 (23%) bacterial agents from 55 (19%) patients. Targeted treatment was used significantly more often in the POC-PCR compared with the SCO group at both 4 h and 48 h but not at day 5 (Table 3). Analysis of adequate treatment did not show a statistically significant difference between the groups at 4 h but more patients were treated with adequate antibiotics at 48 h and on day 5 in the POC-PCR compared to the SCO group (Table 3). A graphical presentation of changes in (2A) no or narrow, (2B) targeted, and (2C) adequate treatment for both groups is presented in Fig 2.

Table 2. Absolute values for “no or narrow (no and narrow), targeted and adequate treatments” at 4 h, 48 h, and day 5. Analyses of targeted and adequate treatment were based on 55 positive culture results from 290 patients.

Patients with prescriptions of “no or narrow” antibiotics									
Timeline	4 hours, <i>n</i> = 291			48 hours, <i>n</i> = 291			5th day, <i>n</i> = 290		
	POC-PCR ¹ 145 (49.8%)	SCO ² 146 (50.2%)	Total 291 (100%)	POC-PCR ¹ 145 (49.8%)	SCO ² 146 (50.2%)	Total 291 (100%)	POC-PCR ¹ 144 (49.7%)	SCO ² 146 (50.3%)	Total 290 (99.7%)
No or Narrow antibiotic	91 (62.8%)	87 (59.6%)	178 (61.2%)	88 (60.7%)	90 (61.6%)	178 (61.2%)	88 (61.1%)	95 (65.1%)	183 (63.1%)
-No antibiotic	30 (20.7%)	29 (19.9%)	59 (20.3%)	31 (21.4%)	28 (19.2%)	59 (20.3%)	33 (22.9%)	36 (24.7%)	69 (23.8%)
-Narrow antibiotic	61 (42.1%)	58 (39.7%)	119 (40.9%)	57 (39.3%)	62 (42.4%)	119 (40.9%)	55 (38.2%)	59 (40.4%)	114 (39.3%)
Patients with positive culture results									
Timeline	4 hours, <i>n</i> = 55			48 hours, <i>n</i> = 55			5th day, <i>n</i> = 55		
	POC-PCR ¹ 26 (47%)	SCO ² 29 (53%)	Total 55 (100%)	POC-PCR ¹ 26 (47%)	SCO ² 29 (53%)	Total 55 (100%)	POC-PCR ¹ 26 (47%)	SCO ² 29 (53%)	Total 55 (100%)
Target antibiotic	15 (57.7%)	7 (24.1%)	22 (40.0%)	17 (65.4%)	10 (34.5%)	27 (49.1%)	14 (53.9%)	15 (51.7%)	29 (52.7%)
Adequate antibiotic	19 (73.1%)	17 (58.6%)	36 (65.5%)	20 (76.9%)	18 (62.1%)	38 (69.1%)	19 (73.1%)	19 (65.5%)	38 (69.1%)

¹POC-PCR in addition to routine culture.

²SCO.

POC-PCR, point-of-care polymerase chain reaction; SCO, standard care only.

<https://doi.org/10.1371/journal.pmed.1004314.t002>

Table 3. Unadjusted and adjusted per protocol analyses for the primary and secondary outcomes: Prescriptions of no or narrow, targeted, and adequate antibiotic treatment at 4 h, 48 h, and day 5. The control group (SCO) is the reference. Analyses of targeted and adequate treatment were based on 55 positive culture results and routine PCR from 290 patients.

Timeline	4 hours (n = 291)		48 hours (n = 291)		5 days (n = 290)	
	OR (95% CI)	p-Value	OR (95% CI)	p-Value	OR (95% CI)	p-Value
Primary outcome						
No or narrow antibiotic	1.14 (0.97; 1.34)	0.101	-	-	-	-
Adjusted for triage	1.05 (0.73; 1.51)	0.772				
Secondary outcomes						
No or narrow antibiotic	-	-	0.96 (0.87; 1.04)	0.373	0.84 (0.73; 0.97)	0.021
Adjusted for triage	-	-	0.91 (0.82; 1.00)	0.065	0.81 (0.72; 0.91)	0.001
Timeline	4 hours (n = 55)		48 hours (n = 55)		5 days (n = 55)	
Secondary outcomes						
Target antibiotic	4.28 (2.51; 7.32)	<0.001	3.58 (1.39; 9.26)	0.008	1.09 (0.65; 1.83)	0.749
Adjusted for triage	5.68 (2.49; 12.94)	<0.001	4.20 (1.87; 9.40)	<0.001	1.08 (0.61; 1.91)	0.786
Adequate antibiotic	1.91 (0.68; 5.40)	0.219	2.04 (1.32; 3.14)	0.001	1.43 (1.33; 1.54)	<0.001
Adjusted for triage	2.11 (0.56; 7.96)	0.267	2.11 (1.23; 3.61)	0.006	1.40 (1.18; 1.66)	<0.001

CI, confidence interval; OR, odds ratio; PCR, polymerase chain reaction; SCO, standard care only.

<https://doi.org/10.1371/journal.pmed.1004314.t003>

Table 4. Adverse events and LOS for 291 patients.

Adverse events	SCO	POC-PCR	OR (95% CI) p-value	OR (95% CI) p-value
	Event (n = 146)	Event (n = 145)	Crude	Adjusted for triage
30 Days mortality ¹	4	5	1.26 (0.33; 4.81) 0.728	1.24 (0.32; 4.82) 0.749
In-hospital mortality ²	3	3	1.00 (0.19; 5.07) 0.993	0.98 (0.19; 5.06) 0.986
Admission to ICU ³	5	2	0.39 (0.07; 2.06) 0.271	0.54 (0.10; 2.91) 0.475
Readmission to hospital ⁴	20	17	0.83 (0.41; 1.67) 0.614	0.90 (0.43; 1.86) 0.787
Adverse events in total ⁵	32	27	0.96 (0.51; 1.77) 0.896	1.04 (0.55; 1.97) 0.899
	Days	Days	IRR (95% CI) p-value	
LOS ⁶ (average in days)	5.2	4.2	0.80 (0.62; 1.04), 0.098	
Adjusted for triage	4.3	3.6	0.82 (0.63; 1.07), 0.164	

¹Mortality within 30 days from admission to the ED.

²Patient mortality during the current hospitalisation.

³Transfer to ICU during the current hospitalisation.

⁴Admission within a 30-day period after discharge from current admission.

⁵Total of numbers of adverse events per patient.

⁶Defined as the time (in days) spent in hospital during the current admission (days from admission to hospital discharge).

CI, confidence interval; ED, emergency department; ICU, intensive care unit; LOS, length of stay; OR, odds ratio; POC-PCR, point-of-care polymerase chain reaction; SCO, standard care only.

<https://doi.org/10.1371/journal.pmed.1004314.t004>

Adverse events

There were no statistically significant differences between POC-PCR and SCO regarding patient 30-day mortality, in-hospital mortality, admission to ICU, 30-day readmission, and LOS (Table 4).




Fig 2. Changes in (2A) no or narrow-, (2B) targeted-, and (2C) adequate treatment prescription at 4 h, 48 h, and day 5. Targeted and adequate treatments are based on culture results and routine PCR and include a sample of 55 patients. Results were adjusted for triage. POC-PCR, point-of-care polymerase chain reaction; SCO, standard care only.

<https://doi.org/10.1371/journal.pmed.1004314.g002>

Discussion

In this randomised study, adding sputum-POC-PCR to our diagnostic setup did not affect prescriptions of no or narrow-spectrum antibiotics during the first 2 days of admission, but less patients in the POC-PCR-group were treated with no or narrow-spectrum antibiotics after 5 days. Interestingly, patients in the POC-PCR-group were more likely to receive early targeted and adequate treatment. Number of readmissions, ICU admissions, and mortality were unchanged but we found a nonsignificant one-day reduction in LOS. Several prospective studies have reported sputum-POC-PCR as a method to support clinical decisions by fast and accurate detection of CAP pathogens [21–23,35]. Studies have shown a reduction in both use of intravenous antibiotics and number of days treated with antibiotics. In contrast to our study, most previous studies in ED settings only used panels for detecting upper respiratory pathogens [25,26,36,37].

Our outcomes were different focusing on type of antibiotic instead of length of treatment and route of administration, but nevertheless, the failure of POC-PCR to increase the use of no or narrow-spectrum antibiotics may seem to contrast these previous results.

There are some likely explanations. In an international context, the level of antimicrobial resistance is very low in Denmark and most pneumococci and *H. influenzae* are susceptible to penicillins [10]. Consequently, Danish treatment guidelines recommend relatively narrow-spectrum penicillins for CAP and reserve broad-spectrum antibiotics for severe pneumonia and/or sepsis [11,12]. This may have affected the study. For example, a patient with severe CAP may have been treated with penicillin instead of broad-spectrum antibiotics if POC-PCR detected pneumococci and another patient with mild CAP may have been treated with broad-spectrum antibiotics instead of penicillin if POC-PCR detected *M. catarrhalis*. Both actions were in agreement with the provided action card and both actions would result in a more targeted treatment—but also blur the effect of POC-PCR. This explanation is in line with the observation that patients in the POC-PCR group were more likely to receive early targeted and adequate treatment. In addition, the detection of *Enterobacteriales* and *Pseudomonas aeruginosa* with POC-PCR may result in broad antimicrobial therapy even though they rarely cause CAP in a medical ED [38]. We excluded *Enterobacteriales* from the analysis of targeted and adequate treatment due to the low incidence (1.3%) and because they usually represent colonisation [38].

Another possible explanation is the very low prevalence of common respiratory viruses in the study period related to the SARS-CoV-2 pandemic [39]. In other studies, virus accounted for 20% to 40% of CAP cases [19,20,37]. Some patients with CAP and a detected viral cause

may be treated without antibiotics, and it is therefore possible that POC-PCR would have reduced the use of antibiotics in a period with a higher transmission of respiratory viruses.

The increased prescription of targeted and adequate antibiotics in the POC-PCR-group within the first 2 days is an interesting observation. It is based on analysis of a small subset of culture-positive samples; therefore, it is unknown if the result completely or in part can be extrapolated to the rest of the study population. Nevertheless, it highlights the question if POC-PCR improves patient outcome. We did not find any difference in mortality or transferal to ICU—but the number of events was very low. There was no difference in the number of readmissions but we did find a nonsignificant reduction in LOS from 4.3 to 3.6 days ($p = 0.164$) when adjusted for triage. It was not significant, but it might on the other hand reflect improved patient treatment and a possible reduction in LOS of almost 20% for one of the most common infections in the ED is very interesting from a hospital management and economic perspective.

At day 5, more patients in the SCO group were treated with no or narrow-spectrum antibiotics and there was no difference in the use of targeted antibiotics. This observation may be explained by routine microbiological results being available between day 2 and 5—allowing adjustment of treatment. Even though, we detected statistically significant differences they might be without clinical significance as they were quite small and day 5 is at the end of our recommended treatment duration. The strength of our study is the pragmatic multicentre, RCT design. The randomised design ensured that severity of illness, CAP diagnosis, and other patient characteristics were distributed equally between intervention and control group, and therefore causal inference is likely as the assumption of positivity is fulfilled. The POC-PCR analysis was integrated in the usual workflow in our ED suggesting that the test is technically feasible and easy to implement in other EDs. Project assistants were trained in collecting LRT-specimens and in using the POC-PCR platform and the primary investigator monitored the project closely to ensure a high level of internal validity. Almost 80% of the collected samples were tracheal secretions and this may have increased the reliability of the microbiological results by reducing upper airway contamination [40,41]. To ensure a uniform and correct clinical interpretation, we provided all POC-PCR results with a clear guideline-based action card.

There are also a number of limitations. Only few patients with CURB-65 scores ≥ 3 (14.4%) were included in the study. The inability to consent is likely linked to severe disease and acute cognitive impairment. In addition, restriction to weekdays and daytime may have reduced the number of severe cases as admission on weekends and at night are known to be associated with increased mortality and risk of referral to ICU [42]. Therefore, results can only be generalised to patients admitted on weekdays during daytime. In the secondary analysis of targeted and adequate treatment, only few culture-positive samples were included. The sensitivity of culture may be very low, and a high number of patients were treated with antibiotics before admission [43]. We could have circumvented this challenge by also analysing samples in the SCO group with FilmArray with a random disclosure design where results only are available in the intervention group. It would also allow subgroup analysis to investigate the effect of POC-PCR separately in test-positive and test-negative patients. It would straighten the results, leading to evidence-practice recommendations for implementing the test in clinical practice. However, it would be more expensive and may introduce ethical issues [44,45].

Both culture and POC-PCR may detect commensals, which was stated clearly in the provided action card. It is therefore possible that the clinicians in some situations chose to ignore the result—e.g., based on severity of illness, response to current treatment, fear of prescribing inadequate treatment, likelihood of commensal pathogen, and expected virulence of the pathogen [46]. We did not measure to what extent the action card recommendations were followed.

A possible interpretation of the overall results is that the current restrictive prescribing strategy in Denmark may be unable to provide targeted and adequate treatment for some patients. This may be overcome by introducing broad-spectrum empirical regimens—but that would fuel a further rise in resistance, may introduce side effects, and go against our general antimicrobial stewardship interventions. However, as indicated in this study, we might get around this problem by introducing fast and sensitive diagnostic methods. Future studies should focus on (i) the impact of POC-PCR on clinical outcome in a larger scale—e.g., LOS, length of treatment, and patient quality of life; (ii) hospitalisation costs; and (iii) the use of adequate and target treatment in a blinded setup where sensitive molecular methods are applied in both intervention and control groups. In conclusion, in this randomised trial introduction of POC-PCR did not increase the proportion of patients prescribed no or narrow-spectrum antibiotics but it might increase early treatment with adequate and targeted antibiotics and may be associated with a reduced LOS. The results apply to a setting with restrictive use of antibiotics and a very low level of antimicrobial resistance and may be quite different in other settings. Fast and accurate diagnostic tools may aid to maintain a restrictive use of antibiotics in the future.

Supporting information

S1 Table. Empirical treatment guidelines of CAP of the region of Southern Denmark.
(PDF)

S2 Table. Standard care procedures in our emergency departments.
(PDF)

S3 Table. Targets of the Biofire FilmArray Pneumonia Panel plus.
(PDF)

S4 Table. Classification of “Narrow antibiotic” treatment.
(PDF)

S5 Table. Classification of “targeted and adequate” treatment.
(PDF)

S1 Text. CONSORT checklist.
(PDF)

S2 Text. Trial protocol.
(PDF)

S3 Text. Written consent and information form.
(PDF)

S4 Text. Action card.
(PDF)

S5 Text. Data availability and data sharing plan.
(PDF)

Acknowledgments

The authors appreciated the text editing from Caroline Moos, research consultant at the University Hospital of Southern Denmark.

Author Contributions

Conceptualization: Mariana Bichuette Cartulieres, Flemming Schønning Rosenvinge, Christian Backer Mogensen, Thor Aage Skovsted, Steen Lomborg Andersen, Claus Østergaard, Helene Skjøt-arkil.

Data curation: Mariana Bichuette Cartulieres.

Formal analysis: Mariana Bichuette Cartulieres, Andreas Kristian Pedersen.

Funding acquisition: Christian Backer Mogensen, Helene Skjøt-arkil.

Investigation: Christian Backer Mogensen, Helene Skjøt-arkil.

Methodology: Mariana Bichuette Cartulieres, Flemming Schønning Rosenvinge, Christian Backer Mogensen, Steen Lomborg Andersen, Claus Østergaard, Andreas Kristian Pedersen, Helene Skjøt-arkil.

Project administration: Mariana Bichuette Cartulieres, Helene Skjøt-arkil.

Resources: Christian Backer Mogensen.

Supervision: Andreas Kristian Pedersen, Helene Skjøt-arkil.

Visualization: Mariana Bichuette Cartulieres, Flemming Schønning Rosenvinge, Christian Backer Mogensen, Helene Skjøt-arkil.

Writing – original draft: Mariana Bichuette Cartulieres.

Writing – review & editing: Mariana Bichuette Cartulieres, Flemming Schønning Rosenvinge, Christian Backer Mogensen, Thor Aage Skovsted, Steen Lomborg Andersen, Claus Østergaard, Andreas Kristian Pedersen, Helene Skjøt-arkil.

References

1. Søgaard M, Nielsen RB, Schønheyder HC, Nørgaard M, Thomsen RW. Nationwide trends in pneumonia hospitalization rates and mortality, Denmark 1997–2011. *Respir Med.* 2014; 108(8):1214–1222. <https://doi.org/10.1016/j.rmed.2014.05.004> PMID: 24898129
2. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet Infect Dis.* 2018; 18(11):1191–1210. [https://doi.org/10.1016/S1473-3099\(18\)30310-4](https://doi.org/10.1016/S1473-3099(18)30310-4) PMID: 30243584
3. National Institute for Health and Care Excellence. Pneumonia in Adults: Diagnosis and Management—NICE Guideline. London: Royal College of Physicians. NICE; [accessed on 2020 Oct 12]. <https://www.rcplondon.ac.uk/guidelines-policy/pneumonia-adults-diagnosis-and-management-nice-guideline>.
4. Meehan TP, Fine MJ, Krumholz HM, Scinto JD, Galusha DH, Mockalis JT, et al. Quality of care, process, and outcomes in elderly patients with pneumonia. *JAMA.* 1997; 278(23):2080–2084. PMID: 9403422
5. Braykov NP, Morgan DJ, Schweizer ML, Uslan DZ, Kelesidis T, Weisenberg SA, et al. Assessment of empirical antibiotic therapy optimisation in six hospitals: an observational cohort study. *Lancet Infect Dis.* 2014; 14(12):1220–1227. [https://doi.org/10.1016/S1473-3099\(14\)70952-1](https://doi.org/10.1016/S1473-3099(14)70952-1) PMID: 25455989
6. Becerra MB, Becerra BJ, Banta JE, Safdar N. Impact of Clostridium difficile infection among pneumonia and urinary tract infection hospitalizations: an analysis of the Nationwide Inpatient Sample. *BMC Infect Dis.* 2015; 15:254. <https://doi.org/10.1186/s12879-015-0925-9> PMID: 26126606
7. Garau J, Baquero F, Pérez-Trallero E, Pérez JL, Martín-Sánchez AM, García-Rey C, et al. Factors impacting on length of stay and mortality of community-acquired pneumonia. *Clin Microbiol Infect.* 2008; 14(4):322–329. <https://doi.org/10.1111/j.1469-0691.2007.01915.x> PMID: 18190569
8. Webb BJ, Sorensen J, Jephson A, Mecham I, Dean NC. Broad-spectrum antibiotic use and poor outcomes in community-onset pneumonia: a cohort study. *Eur Respir J.* 2019; 54(1). <https://doi.org/10.1183/13993003.00057-2019> PMID: 31023851

9. Bell BG, Schellevis F, Stobberingh E, Goossens H, Pringle M. A systematic review and meta-analysis of the effects of antibiotic consumption on antibiotic resistance. *BMC Infect Dis.* 2014; 14(1):13. <https://doi.org/10.1186/1471-2334-14-13> PMID: 24405683
10. STATENS SERUM INSTITUT National Food Institute TUoD. DANMAP 2021 Use of antimicrobial agents and occurrence of antimicrobial resistance in bacteria from food animals, food and humans in Denmark. DK-2300 Copenhagen; 2021.
11. Sygehusmedicin RfAaD. Baggrundsnotat for hensigtsmæssig anvendelse af antibiotika ved nedre luftvejsinfektioner i almen praksis og på hospital: Rådet for Anvendelse af Dyr Sygehusmedicin; 2016 [accessed on 2021 Aug 08]. <http://www.regioner.dk/media/3996/bgn-antibiotika-nedre-luftvejsinf-vers-1-0-november-2016-267967.pdf>.
12. Rosenvinge FS. Antibiotikavejledning for Region Syddanmark: The region of Southern Denmark 06.10.2021. [accessed on 2022 Sep 22]. <https://ekstern.infonet.regionsyddanmark.dk/Files/Dokument547684.htm>.
13. Mandell LA. Community-acquired pneumonia: An overview. *Postgrad Med.* 2015; 127(6):607–615. <https://doi.org/10.1080/00325481.2015.1074030> PMID: 26224210
14. Savvateeva EN, Rubina AY, Gryadunov DA. Biomarkers of Community-Acquired Pneumonia: A Key to Disease Diagnosis and Management. *Biomed Res Int.* 2019; 2019:1701276. <https://doi.org/10.1155/2019/1701276> PMID: 31183362
15. Chandra A, Nicks B, Maniago E, Nouh A, Limkakeng A. A multicenter analysis of the ED diagnosis of pneumonia. *Am J Emerg Med.* 2010; 28(8):862–865. <https://doi.org/10.1016/j.ajem.2009.04.014> PMID: 20887906
16. Garcia-Vazquez E, Marcos MA, Mensa J, de Roux A, Puig J, Font C, et al. Assessment of the usefulness of sputum culture for diagnosis of community-acquired pneumonia using the PORT predictive scoring system. *Arch Intern Med.* 2004; 164(16):1807–1811. <https://doi.org/10.1001/archinte.164.16.1807> PMID: 15364677
17. Ewig S, Schlochtermeyer M, Goke N, Niederman MS. Applying sputum as a diagnostic tool in pneumonia: limited yield, minimal impact on treatment decisions. *Chest.* 2002; 121(5):1486–1492. <https://doi.org/10.1378/chest.121.5.1486> PMID: 12006433
18. Murphy CN, Fowler R, Balada-Llasat JM, Carroll A, Stone H, Akerele O, et al. Multicenter Evaluation of the BioFire FilmArray Pneumonia/Pneumonia Plus Panel for Detection and Quantification of Agents of Lower Respiratory Tract Infection. *J Clin Microbiol.* 2020; 58(7). <https://doi.org/10.1128/JCM.00128-20> PMID: 32350043
19. Musher DM, Thorner AR. Community-acquired pneumonia. *N Engl J Med.* 2014; 371(17):1619–1628. <https://doi.org/10.1056/NEJMra1312885> PMID: 25337751
20. Gadsby NJ, Russell CD, McHugh MP, Mark H, Conway Morris A, Laurenson IF, et al. Comprehensive Molecular Testing for Respiratory Pathogens in Community-Acquired Pneumonia. *Clin Infect Dis.* 2016; 62(7):817–823. <https://doi.org/10.1093/cid/civ1214> PMID: 26747825
21. Gastli N, Loubinoux J, Daragon M, Lavigne JP, Saint-Sardos P, Pailhoriès H, et al. Multicentric evaluation of BioFire FilmArray Pneumonia Panel for rapid bacteriological documentation of pneumonia. *Clin Microbiol Infect.* 2021; 27(9):1308–1314. <https://doi.org/10.1016/j.cmi.2020.11.014> PMID: 33276137
22. Yoo IY, Huh K, Shim HJ, Yun SA, Chung YN, Kang OK, et al. Evaluation of the BioFire FilmArray Pneumonia Panel for rapid detection of respiratory bacterial pathogens and antibiotic resistance genes in sputum and endotracheal aspirate specimens. *Int J Infect Dis.* 2020; 95:326–331. <https://doi.org/10.1016/j.ijid.2020.03.024> PMID: 32179139
23. Webber DM, Wallace MA, Burnham CA, Anderson NW. Evaluation of the BioFire FilmArray Pneumonia Panel for Detection of Viral and Bacterial Pathogens in Lower Respiratory Tract Specimens in the Setting of a Tertiary Care Academic Medical Center. *J Clin Microbiol.* 2020; 58(7). <https://doi.org/10.1128/JCM.00343-20> PMID: 32321782
24. Rand KH, Beal SG, Cherabuddi K, Couturier B, Lingenfelter B, Rindlisbacher C, et al. Performance of a Semiquantitative Multiplex Bacterial and Viral PCR Panel Compared With Standard Microbiological Laboratory Results: 396 Patients Studied With the BioFire Pneumonia Panel. *Open Forum Infect Dis.* 2021; 8(1):ofaa560. <https://doi.org/10.1093/ofid/ofaa560> PMID: 33447631
25. Shengchen D, Gu X, Fan G, Sun R, Wang Y, Yu D, et al. Evaluation of a molecular point-of-care testing for viral and atypical pathogens on intravenous antibiotic duration in hospitalized adults with lower respiratory tract infection: a randomized clinical trial. *Clin Microbiol Infect.* 2019; 25(11):1415–1421. <https://doi.org/10.1016/j.cmi.2019.06.012> PMID: 31229593
26. Buchan BW, Windham S, Balada-Llasat JM, Leber A, Harrington A, Relich R, et al. Practical Comparison of the BioFire FilmArray Pneumonia Panel to Routine Diagnostic Methods and Potential Impact on Antimicrobial Stewardship in Adult Hospitalized Patients with Lower Respiratory Tract Infections. *J Clin Microbiol.* 2020; 58(7). <https://doi.org/10.1128/JCM.00135-20> PMID: 32350045

27. Serigstad S, Markussen D, Grewal HMS, Ebbesen M, Kommedal Ø, Heggelund L, et al. Rapid syndromic PCR testing in patients with respiratory tract infections reduces time to results and improves microbial yield. *Sci Rep*. 2022; 12(1):326. <https://doi.org/10.1038/s41598-021-03741-7> PMID: 35013351
28. Skjøt-Arkil H, Heltborg A, Lorentzen MH, Cartuliales MB, Hertz MA, Graumann O, et al. Improved diagnostics of infectious diseases in emergency departments: a protocol of a multifaceted multicentre diagnostic study. *BMJ Open*. 2021; 11(9):e049606. <https://doi.org/10.1136/bmjopen-2021-049606> PMID: 34593497
29. Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. *BMJ*. 2010; 340:c869. <https://doi.org/10.1136/bmj.c869> PMID: 20332511
30. KL. Udvikling i indlæggelsestid på somatiske hospitaler 2009–2018 2020 [accessed on 2023 May 5]. <https://www.kl.dk/nyheder/momentum/2020/2020-16/de-aeldste-patienter-er-indlagt-i-markant-kortere-tid/>
31. BioFire. 2018. FilmArray Pneumonia panel instruction booklet RFIT-ASY0144/145. BioFire SLC, UT.
32. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, et al. The REDCap consortium: Building an international community of software platform partners. *J Biomed Inform*. 2019; 95:103208. <https://doi.org/10.1016/j.jbi.2019.103208> PMID: 31078660
33. Hagen TL, Hertz MA, Uhrin GB, Dalager-Pedersen M, Schönheyder HC, Nielsen H. Adherence to local antimicrobial guidelines for initial treatment of community-acquired infections. *Dan Med J*. 2017; 64(6). PMID: 28566116
34. Plesner LL, Iversen AKS, Langkjær S, Nielsen TL, Østervig R, Warming PE, et al. The formation and design of the TRIAGE study-baseline data on 6005 consecutive patients admitted to hospital from the emergency department. *Scand J Trauma Resusc Emerg Med*. 2015; 23(1):1–9. <https://doi.org/10.1186/s13049-015-0184-1> PMID: 26626588
35. Edin A, Eilers H, Allard A. Evaluation of the Biofire Filmarray Pneumonia panel plus for lower respiratory tract infections. *Infect Dis (Lond)*. 2020; 52(7):479–488. <https://doi.org/10.1080/23744235.2020.1755053> PMID: 32319831
36. Echavarría M, Marcone DN, Querci M, Seoane A, Ypas M, Videla C, et al. Clinical impact of rapid molecular detection of respiratory pathogens in patients with acute respiratory infection. *J Clin Virol*. 2018; 108:90–95. <https://doi.org/10.1016/j.jcv.2018.09.009> PMID: 30267999
37. Yang S, Li H, Tang Y, Yu F, Ma C, Zhang H, et al. Multiplex Tests for Respiratory Tract Infections: The Direct Utility of the FilmArray Respiratory Panel in Emergency Department. *Can Respir J*. 2020; 2020:6014563. <https://doi.org/10.1155/2020/6014563> PMID: 32774562
38. von Baum H, Welte T, Marre R, Suttorp N, Ewig S. Community-acquired pneumonia through Enterobacteriaceae and *Pseudomonas aeruginosa*: Diagnosis, incidence and predictors. *Eur Respir J*. 2010; 35(3):598–605. <https://doi.org/10.1183/09031936.00091809> PMID: 19679601
39. Institut SS. Influenza season 2020–2021—report on disease occurrence. 2021 [accessed on 2022 Aug 29]. <https://en.ssi.dk/surveillance-and-preparedness/surveillance-in-denmark/annual-reports-on-disease-incidence/influenza-season-2020-2021—report-on-disease-occurrence>.
40. Nagendra S, Bourbeau P, Brecher S, Dunne M, LaRocco M, Doern G. Sampling variability in the microbiological evaluation of expectorated sputa and endotracheal aspirates. *J Clin Microbiol*. 2001; 39(6):2344–2347. <https://doi.org/10.1128/JCM.39.6.2344-2347.2001> PMID: 11376088
41. Cartuliales MB, Rosenvinge FS, Mogensen CB, Skovsted TA, Andersen SL, Pedersen AK, et al. Expiratory Technique versus Tracheal Suction to Obtain Good-Quality Sputum from Patients with Suspected Lower Respiratory Tract Infection: A Randomized Controlled Trial. *Diagnostics (Basel)*. 2022; 12(10). <https://doi.org/10.3390/diagnostics12102504> PMID: 36292193
42. Vest-Hansen B, Riis AH, Sørensen HT, Christiansen CF. Out-of-hours and weekend admissions to Danish medical departments: admission rates and 30-day mortality for 20 common medical conditions. *BMJ Open*. 2015; 5(3):e006731. <https://doi.org/10.1136/bmjopen-2014-006731> PMID: 25762233
43. Musher DM, Montoya R, Wanahita A. Diagnostic value of microscopic examination of Gram-stained sputum and sputum cultures in patients with bacteremic pneumococcal pneumonia. *Clin Infect Dis*. 2004; 39(2):165–169. <https://doi.org/10.1086/421497> PMID: 15307023
44. Werner Vach VR, Kolankowska I, Weber S, Rücker G. Design and Evaluation of Diagnostic Studies: Bundensministerium für Bildung und Forschung; 2017.
45. Hot A, Bossuyt PM, Gerke O, Wahl S, Vach W, Zapf A. Randomized test-treatment studies with an outlook on adaptive designs. *BMC Med Res Methodol*. 2021; 21(1):110. <https://doi.org/10.1186/s12874-021-01293-y> PMID: 34074263
46. Schouten JA, Hulscher ME, Natsch S, Kullberg BJ, van der Meer JW, Grol RP. Barriers to optimal antibiotic use for community-acquired pneumonia at hospitals: a qualitative study. *Qual Saf Health Care*. 2007; 16(2):143–149. <https://doi.org/10.1136/qshc.2005.017327> PMID: 17403764